- Home
- CRDL vs NNBR Comparison
CRDL vs NNBR Comparison
Compare CRDL & NNBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- NNBR
- Stock Information
- Founded
- CRDL 2017
- NNBR 1980
- Country
- CRDL Canada
- NNBR United States
- Employees
- CRDL N/A
- NNBR N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- NNBR Industrial Machinery/Components
- Sector
- CRDL Health Care
- NNBR Industrials
- Exchange
- CRDL Nasdaq
- NNBR Nasdaq
- Market Cap
- CRDL 126.5M
- NNBR 129.3M
- IPO Year
- CRDL N/A
- NNBR 1994
- Fundamental
- Price
- CRDL $1.05
- NNBR $2.51
- Analyst Decision
- CRDL Strong Buy
- NNBR
- Analyst Count
- CRDL 2
- NNBR 0
- Target Price
- CRDL $9.00
- NNBR N/A
- AVG Volume (30 Days)
- CRDL 1.2M
- NNBR 72.7K
- Earning Date
- CRDL 08-14-2025
- NNBR 10-29-2025
- Dividend Yield
- CRDL N/A
- NNBR N/A
- EPS Growth
- CRDL N/A
- NNBR N/A
- EPS
- CRDL N/A
- NNBR N/A
- Revenue
- CRDL N/A
- NNBR $433,709,000.00
- Revenue This Year
- CRDL N/A
- NNBR N/A
- Revenue Next Year
- CRDL N/A
- NNBR $4.88
- P/E Ratio
- CRDL N/A
- NNBR N/A
- Revenue Growth
- CRDL N/A
- NNBR N/A
- 52 Week Low
- CRDL $0.77
- NNBR $1.58
- 52 Week High
- CRDL $2.63
- NNBR $4.67
- Technical
- Relative Strength Index (RSI)
- CRDL 39.49
- NNBR 57.36
- Support Level
- CRDL $1.12
- NNBR $2.41
- Resistance Level
- CRDL $1.14
- NNBR $2.63
- Average True Range (ATR)
- CRDL 0.07
- NNBR 0.13
- MACD
- CRDL -0.00
- NNBR 0.00
- Stochastic Oscillator
- CRDL 5.56
- NNBR 69.23
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About NNBR NN Inc.
NN Inc is a diversified industrial company that combines engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision solutions and components. It operates in two business segments: mobile solutions and power solutions. The mobile solutions segment involves growth in the general industrial and automotive end markets. Its power solutions segment involves growth in the electrical and aerospace and defense end markets.